US Fexofenadine Hydrochloride Market Softens on Comfortable Imports

US Fexofenadine Hydrochloride prices softened in July 2026 as seasonal allergy demand cooled after the spring peak and comfortable imports from India and China reduced spot urgency. Improved container availability and predictable lead times supported steady Gulf Coast arrivals, while finished-dose recalls temporarily increased downstream inventories and encouraged manufacturers to reduce API call-offs. Retail and OTC demand weakened, although hospital and mail-order purchasing remained stable. Indian and Chinese producers maintained regular shipments without new supply curbs, keeping availability comfortable despite higher freight costs on the India–USA route. Looking ahead to August, the Fexofenadine Hydrochloride market is expected to see mild upward pressure as pharmaceutical manufacturers and distributors begin pre-autumn restocking. Prompt material could be absorbed more quickly as buyers rebuild coverage ahead of seasonal demand, supporting a gradual recovery. However, existing inventories, steady imports, and potentially softer demand after restocking could limit gains. The August outlook remains cautiously firm and subject to shipping costs, manufacturer call-offs, and procurement behavior.